Rep. Marjorie Taylor Greene Buys AbbVie Inc. (NYSE:ABBV) Stock

Representative Marjorie Taylor Greene (R-Georgia) recently bought shares of AbbVie Inc. NYSE: ABBV. In a filing disclosed on May 06th, the Representative disclosed that they had bought between $1,001 and $15,000 in AbbVie stock on May 5th. The trade occurred in the Representative's "MARJORIE IRA" account.

Representative Marjorie Taylor Greene also recently made the following trade(s):

• Purchased $1,001 - $15,000 in shares of Occidental Petroleum NYSE: OXY on 5/5/2025.
• Purchased $1,001 - $15,000 in shares of Paychex NASDAQ: PAYX on 5/5/2025.
• Purchased $1,001 - $15,000 in shares of MercadoLibre NASDAQ: MELI on 5/5/2025.
• Purchased $1,001 - $15,000 in shares of Starbucks NASDAQ: SBUX on 5/5/2025.
• Purchased $1,001 - $15,000 in shares of BP NYSE: BP on 5/5/2025.
• Purchased $1,001 - $15,000 in shares of Gilead Sciences NASDAQ: GILD on 5/5/2025.
• Purchased $1,001 - $15,000 in shares of BHP Group NYSE: BHP on 5/5/2025.
• Purchased $1,001 - $15,000 in shares of Advanced Micro Devices NASDAQ: AMD on 5/5/2025.
• Purchased $1,001 - $15,000 in shares of Alphabet NASDAQ: GOOG on 5/5/2025.
• Purchased $1,001 - $15,000 in shares of Impinj NASDAQ: PI on 5/5/2025.

AbbVie Stock Performance

AbbVie stock traded down $1.28 during mid-day trading on Friday, hitting $184.30. 7,806,084 shares of the company's stock traded hands, compared to its average volume of 6,112,684. The company has a quick ratio of 0.55, a current ratio of 0.66 and a debt-to-equity ratio of 17.94. AbbVie Inc. has a one year low of $153.58 and a one year high of $218.66. The firm has a 50 day moving average price of $194.70 and a 200 day moving average price of $187.26. The company has a market cap of $326.02 billion, a PE ratio of 76.79, a price-to-earnings-growth ratio of 1.62 and a beta of 0.56.

AbbVie (NYSE:ABBV - Get Free Report) last issued its quarterly earnings results on Friday, April 25th. The company reported $2.46 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.40 by $0.06. The firm had revenue of $13.34 billion during the quarter, compared to analyst estimates of $12.91 billion. AbbVie had a return on equity of 296.28% and a net margin of 7.59%. The firm's quarterly revenue was up 8.4% on a year-over-year basis. During the same period last year, the company posted $2.31 EPS. On average, equities analysts forecast that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, May 15th. Stockholders of record on Tuesday, April 15th will be given a dividend of $1.64 per share. The ex-dividend date of this dividend is Tuesday, April 15th. This represents a $6.56 annualized dividend and a dividend yield of 3.56%. AbbVie's dividend payout ratio is presently 279.15%.

Analyst Ratings Changes

Several analysts have issued reports on the company. Citigroup boosted their price objective on AbbVie from $205.00 to $215.00 and gave the stock a "buy" rating in a report on Monday, February 3rd. Bank of America boosted their price target on AbbVie from $200.00 to $223.00 and gave the stock a "neutral" rating in a research report on Tuesday, March 4th. StockNews.com upgraded shares of AbbVie from a "buy" rating to a "strong-buy" rating in a research note on Monday, April 28th. UBS Group upped their price target on AbbVie from $181.00 to $190.00 and gave the stock a "neutral" rating in a report on Monday, February 3rd. Finally, BMO Capital Markets raised their price objective on AbbVie from $208.00 to $215.00 and gave the stock an "outperform" rating in a research report on Monday, February 3rd. Six equities research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and four have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $211.41.

Insider Activity

In other AbbVie news, EVP Timothy J. Richmond sold 29,917 shares of the business's stock in a transaction dated Wednesday, February 26th. The stock was sold at an average price of $202.90, for a total transaction of $6,070,159.30. Following the completion of the sale, the executive vice president now owns 44,284 shares of the company's stock, valued at approximately $8,985,223.60. The trade was a 40.32 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Jeffrey Ryan Stewart sold 58,832 shares of the firm's stock in a transaction that occurred on Monday, March 31st. The stock was sold at an average price of $210.08, for a total transaction of $12,359,426.56. Following the sale, the executive vice president now owns 53,234 shares in the company, valued at approximately $11,183,398.72. The trade was a 52.50 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 113,471 shares of company stock worth $23,426,451 over the last 90 days. 0.08% of the stock is currently owned by insiders.

Hedge Funds Weigh In On AbbVie

A number of hedge funds and other institutional investors have recently made changes to their positions in ABBV. Crestline Management LP lifted its position in AbbVie by 438.4% during the fourth quarter. Crestline Management LP now owns 35,311 shares of the company's stock valued at $6,275,000 after buying an additional 28,753 shares during the period. Dimensional Fund Advisors LP raised its stake in AbbVie by 1.2% during the fourth quarter. Dimensional Fund Advisors LP now owns 9,367,162 shares of the company's stock valued at $1,664,489,000 after buying an additional 108,993 shares during the last quarter. Quantbot Technologies LP raised its position in shares of AbbVie by 35.8% in the 4th quarter. Quantbot Technologies LP now owns 1,047 shares of the company's stock worth $186,000 after purchasing an additional 276 shares during the last quarter. AXA S.A. boosted its stake in AbbVie by 14.8% in the 4th quarter. AXA S.A. now owns 971,893 shares of the company's stock worth $172,705,000 after purchasing an additional 125,568 shares in the last quarter. Finally, Sky Investment Group LLC grew its position in AbbVie by 10.1% during the 4th quarter. Sky Investment Group LLC now owns 42,715 shares of the company's stock valued at $7,590,000 after purchasing an additional 3,936 shares during the last quarter. Institutional investors own 70.23% of the company's stock.

About Representative Greene

Marjorie Taylor Greene (Republican Party) is a member of the U.S. House, representing Georgia's 14th Congressional District. She assumed office on January 3, 2021. Her current term ends on January 3, 2027. Greene (Republican Party) is running for re-election to the U.S. House to represent Georgia's 14th Congressional District. She declared candidacy for the 2026 election.

About AbbVie

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.